ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
musk6210
|
649 |
159K |
3 |
26/06/24 |
26/06/24 |
ASX - By Stock
|
649
|
159K
|
3
|
|
ASX - By Stock
|
PAA Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
musk6210
|
649 |
159K |
10 |
25/06/24 |
25/06/24 |
ASX - By Stock
|
649
|
159K
|
10
|
|
ASX - By Stock
|
PAA Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
musk6210
|
58 |
13K |
8 |
10/06/24 |
10/06/24 |
ASX - By Stock
|
58
|
13K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
PharmAust reappoints MD and resets its sights on MND battle
|
|
musk6210
|
15 |
4.7K |
13 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
15
|
4.7K
|
13
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
musk6210
|
1.4K |
365K |
7 |
13/04/24 |
13/04/24 |
ASX - By Stock
|
1.4K
|
365K
|
7
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
musk6210
|
222 |
49K |
3 |
18/03/24 |
18/03/24 |
ASX - By Stock
|
222
|
49K
|
3
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
musk6210
|
77 |
21K |
2 |
08/03/24 |
08/03/24 |
ASX - By Stock
|
77
|
21K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Big Pharma buyouts.
|
|
musk6210
|
39 |
9.7K |
10 |
27/02/24 |
27/02/24 |
ASX - By Stock
|
39
|
9.7K
|
10
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notice of General Meeting & Proxy Form
|
|
musk6210
|
8 |
2.5K |
2 |
21/02/24 |
21/02/24 |
ASX - By Stock
|
8
|
2.5K
|
2
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Notice of General Meeting & Proxy Form
|
|
musk6210
|
8 |
2.5K |
4 |
16/02/24 |
16/02/24 |
ASX - By Stock
|
8
|
2.5K
|
4
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
musk6210
|
1 |
737 |
9 |
13/02/24 |
13/02/24 |
ASX - By Stock
|
1
|
737
|
9
|
|
ASX - By Stock
|
PAA Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
musk6210
|
1.4K |
365K |
7 |
09/02/24 |
09/02/24 |
ASX - By Stock
|
1.4K
|
365K
|
7
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Partners with Berry Consultants for MND Phase 2/3
|
|
musk6210
|
98 |
24K |
16 |
16/01/24 |
16/01/24 |
ASX - By Stock
|
98
|
24K
|
16
|
|
ASX - By Stock
|
PAA |
Re:
Ann: PharmAust Partners with Berry Consultants for MND Phase 2/3
|
|
musk6210
|
98 |
24K |
13 |
16/01/24 |
16/01/24 |
ASX - By Stock
|
98
|
24K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Application for quotation of securities - PAA
|
|
musk6210
|
10 |
2.4K |
0 |
18/12/23 |
18/12/23 |
ASX - By Stock
|
10
|
2.4K
|
0
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Options Offer to Existing Listed Option Holders
|
|
musk6210
|
79 |
16K |
11 |
18/10/23 |
18/10/23 |
ASX - By Stock
|
79
|
16K
|
11
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Additional Phase 1 data suggest MPL may inhibit MND
|
|
musk6210
|
380 |
85K |
8 |
03/10/23 |
03/10/23 |
ASX - By Stock
|
380
|
85K
|
8
|
|
ASX - By Stock
|
PAA |
Re:
Ann: Commencement of Cohort 3 in Phase 1/2 MND Trial
|
|
musk6210
|
151 |
32K |
15 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
151
|
32K
|
15
|
|
ASX - By Stock
|
PAA |
Re:
Ann: MPL has anti-cancer effects across multiple cancer types
|
|
musk6210
|
121 |
27K |
13 |
09/05/23 |
09/05/23 |
ASX - By Stock
|
121
|
27K
|
13
|
|
ASX - By Stock
|
PAA |
Re:
Interactive AGM Yes/No vote
|
|
musk6210
|
87 |
13K |
9 |
15/02/23 |
15/02/23 |
ASX - By Stock
|
87
|
13K
|
9
|
|
ASX - By Stock
|
ADN |
Re:
General comments/chat
|
|
musk6210
|
43K |
20M |
1 |
13/12/22 |
13/12/22 |
ASX - By Stock
|
43K
|
20M
|
1
|
|
ASX - By Stock
|
ADN |
Re:
General comments/chat
|
|
musk6210
|
43K |
20M |
3 |
13/12/22 |
13/12/22 |
ASX - By Stock
|
43K
|
20M
|
3
|
|
ASX - By Stock
|
PAR |
Re:
Motor neuron disease (MND) and inflammation
|
|
musk6210
|
4 |
1.9K |
1 |
29/11/21 |
29/11/21 |
ASX - By Stock
|
4
|
1.9K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Valuation of PAR
|
|
musk6210
|
79 |
32K |
4 |
04/10/21 |
04/10/21 |
ASX - By Stock
|
79
|
32K
|
4
|
|
ASX - By Stock
|
PAR |
Re:
Pirate Day Share Price 2021
|
|
musk6210
|
162 |
62K |
0 |
24/04/21 |
24/04/21 |
ASX - By Stock
|
162
|
62K
|
0
|
|